ESC 365 - Ultra-low-dose twice-daily aspirin improves haemostasis and maintains platelet inhibition in acute coronary syndrome patients receiving ticagrelor

ACVC Premium Access

Ultra-low-dose twice-daily aspirin improves haemostasis and maintains platelet inhibition in acute coronary syndrome patients receiving ticagrelor

Session: Anti-thrombotics in patients at simultaneous risk of stroke and stent thrombosis

Topic: Acute Coronary Syndromes: Antiplatelet Agents

Speaker: Doctor W. Parker (Sheffield, GB)

Event: Acute Cardiovascular Care 2018

Congress Presentation

Add to my library

About the speaker

Doctor William Parker

University of Sheffield, Sheffield (United Kingdom of Great Britain & Northern Ireland)

1 follower

4 more presentations in this session

Why do we need to combine antiplatelets and anticoagulants?

Speaker: Professor R. De Caterina (Pisa, IT)

Rational to remove aspirin from the cocktail. The story after WOEST...(VIA ZOOM)

Speaker: Professor J. ten Berg (Nieuwegein, NL)

What have we learned in the era of NOACs.

Speaker: Professor F. Verheugt (Amsterdam, NL)

Type of stent, type of antiplatelet, type of anticoagulant. The triad of success.

Speaker: Doctor G. Casella (Bologna, IT)

Access the full session

Anti-thrombotics in patients at simultaneous risk of stroke and stent thrombosis

Speakers: Doctor W. Parker, Professor R. De Caterina, Professor J. ten Berg, Professor F. Verheugt, Doctor G. Casella

About the event

Acute Cardiovascular Care 2018

3 March - 5 March 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources